Bioerodible episcleral implant for sustained drug delivery to the retina
概要
Vinci Pharmaceuticals is a specialty ophthalmic company in Avon-by-the-Sea, New Jersey. Its EPIPLANT platform is a bioerodible episcleral implant for sustained, needle-free drug delivery to retinal tissue. The platform was licensed from the Retina Foundation of the Southwest. A first-in-human Phase 1/2a study is planned for 2027.